BACKGROUND/PURPOSE
Denosumab effectively increases bone mineral density (BMD) and reduces fracture risk in osteoporosis patients. Denosumab discontinuation is related with rebound bone loss and increased fracture risk. Zoledronate has been proposed as sequential therapy to mitigate this effect. We investigated the effi...
Hung-Kuan Yen, Ming-Hung Chiang, Shan-Lun Tsao et al.· Journal of the Formosan Medi...· 2 citations
Romosozumab was not associated with an increased risk of incident T2D or other diabetes-related outcomes compared with denosumab, and these findings were supported by calendar-year-specific analyses, although residual confounding and differential follow-up warrant cautious interpretation.
C. Farn, I-Ching Chiang, Hung-Kuan Yen et al.· Diabetes & Metabolism· 0 citations
Background: Randomized controlled trials (RCTs) and meta-analyses have generally reported comparable short-term outcomes between hamstring tendon (HT) and quadriceps tendon (QT) autografts for anterior cruciate ligament reconstruction (ACLR). However, the statistical robustness of these nonsignificant continuous outcom...
Tzu-Hao Tseng, Shau-Huai Fu, Yao-Chang Lo et al.· Orthopaedic Journal of Sport...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.